Biogen (BIIB)
(Delayed Data from NSDQ)
$236.72 USD
+2.59 (1.11%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $236.76 +0.04 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Brokerage Reports
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 781 - 800 ( 803 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Encouraging data on MS drugs, such as BG-12 & Daclizumab, brings in a ray of hope for improvement in growth prospects...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Encouraging data on oral MS drug, BG-12, raises hopes of strong growth ahead....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Moderate Outperform : Encouraging data on oral MS drug, BG-12, raises hopes of strong growth ahead....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Disappointing sales performance by Tysabri & further competition expected from launch of Novartis?
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Tysabri?s poor off take & disappointing momentum in weekly additions raises.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Concern remains over likely implementation of price cuts in Europe in Q3 CY10 & lack of meaningful catalysts in 2010
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Performance of Tysabri holds key to overall growth in near term
Provider: FIRST GLOBAL
Analyst: THOMAS K